SCHEMBL9877006

SCHEMBL9877006

COc1cc(OC)nc(N=C=S)n1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
APLNR P35414 1/20 0.37
CYP1A2 P05177 1/20 0.36
PDE2A O00408 1/20 0.36
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 2/20 0.34
RECQL P46063 1/20 0.34
MIF P14174 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HPGD P15428 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10394269 0.89 L3MBTL1 (0.39) L3MBTL1SMN1; SMN2APLNRCYP1A2PDE2A
SCHEMBL2704089 0.81 L3MBTL1 (0.48) L3MBTL1SMN1; SMN2LMNACYP1A2PDE2A
SCHEMBL10509802 0.74 APLNR (0.35) APLNRALDH1A1MIF
SCHEMBL9517836 0.73 L3MBTL1 (0.41) L3MBTL1SMN1; SMN2LMNAAPLNRCYP1A2
SCHEMBL28377189 0.71 L3MBTL1 (0.52) L3MBTL1SMN1; SMN2LMNACYP1A2PDE2A
SCHEMBL10394994 0.71 POLB (0.37) LMNACYP1A2ALDH1A1KDM4EMIF
SCHEMBL484216 0.71 MIF (0.35) CYP1A2ALDH1A1MIFTDP1HPGD
SCHEMBL10647845 0.70 L3MBTL1 (0.50) L3MBTL1SMN1; SMN2LMNACYP1A2PDE2A
SCHEMBL8446835 0.69 GAA (0.43) L3MBTL1SMN1; SMN2LMNACYP1A2ALDH1A1
SCHEMBL5573217 0.69 GABRP (0.33) CYP1A2ALDH1A1MIFTDP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3541802-B1 ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2025-01-01 EP disclosed
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 US disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
EP-3541804-A1 CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR Amgen Inc. (US) 2019-09-25 EP disclosed
WO-2018093577-A1 CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2018-05-24 WO disclosed
US-9868721-B2 Triazole agonists of the APJ receptor AMGEN INC. (US) 2018-01-16 US disclosed
US-9656998-B2 Intermediates for preparing triazole agonists of the APJ receptor AMGEN INC. (US) 2017-05-23 US disclosed
US-20170042897-A1 TRIAZOLE AGONISTS OF THE APJ RECEPTOR AMGEN INC. 2017-02-16 US disclosed
US-20170037026-A1 TRIAZOLE AGONISTS OF THE APJ RECEPTOR AMGEN INC. 2017-02-09 US disclosed
US-5069709-A PRE-AND POSTEMERGENCE; PLANT GROWTH REGULATORS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-12-03 US disclosed
CN-1041592-A Sultamsulfonamide derivatives and weedicide NISSAN CHEMICAL IND LTD (JP) 1990-04-25 CN disclosed
US-4897105-A (1,2,4)-THIADIAZOLO(2,3-A)PYRIMIDINE DERIVATIVES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1990-01-30 US disclosed
EP-0342456-A2 Sultamsulfonamide derivatives and herbicides NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1989-11-23 EP disclosed
US-4872901-A PREFERENTIAL TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1989-10-10 US disclosed
CN-87102275-A Selective herbicide and manufacturing thereof and use 1988-02-17 CN disclosed
EP-0239064-A2 Herbicidal compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1987-09-30 EP disclosed
EP-0220695-A1 Herbicidal compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1987-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AGTR1, AGTR2, TBXA2R L3MBTL1 4800/4885SMN1; SMN2 4728/4885LMNA 3334/4885
US-20170037026-A1 TRIAZOLE AGONISTS OF THE APJ RECEPTOR TBXA2R, AGTR1, AGTR2 L3MBTL1 4796/4885SMN1; SMN2 4804/4885LMNA 3741/4885
US-20170042897-A1 TRIAZOLE AGONISTS OF THE APJ RECEPTOR TBXA2R, AGTR1, AGTR2 L3MBTL1 4796/4885SMN1; SMN2 4804/4885LMNA 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.